Anti-Human CD16/FcgR3 Nanobody (SAA2149) [SAA2149] (HY386023) is a alpaca monoclonal antibody detecting CD16-I in Blocking, ELISA. Suitable for Human.
Species reactivity
Human
Applications
Blocking, ELISA, WB
Host species
Alpaca
Isotype
VHH-8His-Cys-tag
Clone ID
SAA2149
Clonality
Monoclonal
Tested applications
WB
Target
Low affinity immunoglobulin gamma Fc region receptor III-B, Fc-gamma RIII-beta, CD16-I, Fc-gamma RIII, Fc-gamma RIIIb, FcRIII, FcRIIIb, FcR-10, IgG Fc receptor III-1, CD16b, FCGR3B, CD16B, FCG3, FCGR3, IGFR3, Low affinity immunoglobulin gamma Fc region receptor III-A, IgG Fc receptor III-A, CD16-II, CD16a antigen, Fc-gamma RIII-alpha, Fc-gamma RIII, Fc-gamma RIIIa, FcRIII, FcRIIIa, FcgammaRIIIA, FcR-10, IgG Fc receptor III-2, CD16a, FCGR3A, CD16A, FCG3, FCGR3, IGFR3
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
P08637, O75015
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Product Usage Information
Application
Dilution
ELISA
1:2000-1:20000
WB
1:500-1:2000
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Background
Low affinity immunoglobulin gamma Fc region receptor III-A (CD16/FcgR3) is a ~29 kDa protein. Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger. Mediates IgG effector functions on natural killer (NK) cells. Binds antigen-IgG complexes generated upon infection and triggers NK cell-dependent cytokine production and degranulation to limit viral load and propagation.
1. Hezareh, M. et al. (2001) Journal of virology 75, 12161-8. PMID: 11711607
2. Ferrara, C. et al. (2011) Proceedings of the National Academy of Sciences of the United States of America 108, 12669-74. PMID: 21768335
3. Mizushima, T. et al. (2011) Genes to cells : devoted to molecular & cellular mechanisms 16, 1071-80. PMID: 22023369
4. DiLillo, DJ. et al. (2014) Nature medicine 20, 143-51. PMID: 24412922
5. Lee, J. et al. (2015) Immunity 42, 431-42. PMID: 25786175
6. Jing, Y. et al. (2015) PloS one 10, e0121788. PMID: 25816339
7. Blázquez-Moreno, A. et al. (2017) Proceedings of the National Academy of Sciences of the United States of America 114, E5645-E5654. PMID: 28652325
8. de Haas, M. et al. (1996) Journal of immunology (Baltimore, Md. : 1950) 156, 2948-55. PMID: 8609432
SDS-PAGE for Anti-Human CD16/FcgR3 Nanobody (SAA2149).
Bioactivity
Detects recombinant CD16b (Catalog No: HF886011) in indirect ELISA.
Western blot
Western blot analysis was performed using anti-CD16b monoclonal antibody at 1ug/mL on various samples. Lane 1: recombinant human CD16b (Catalog No: HF886011)
中文
English
한국어
日本語
Español
Français
Русский
